COVID-19 disease and immune dysregulation

被引：35

作者：

Davitt, Ethan ^{[1
]}

Davitt, Colin ^{[2
]}

Mazer, Monty B. ^{[3
,5
]}

Areti, Sathya S. ^{[4
]}

Hotchkiss, Richard S. ^{[1
,2
]}

Remy, Kenneth E. ^{[2
,3
,4
,5
,6
]}

机构：

[1] Washington Univ, Sch Med, St Louis, MO USA

[2] Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO USA

[3] Univ Hosp Cleveland, Dept Pediat, Cleveland, OH USA

[4] Univ Hosp Cleveland, Dept Internal Med, Cleveland, OH USA

[5] Case Western Reserve Univ, Sch Med, Cleveland, OH USA

[6] Case Western Reserve Univ, Univ Hosp Cleveland, Sch Med, Dept Internal Med, 11100 Euclid Ave, Cleveland, OH 44106 USA

来源：

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY | 2022年 / 35卷 / 03期

基金：

美国国家卫生研究院;

关键词：

COVID-19; SARS-CoV-2; Immunology; Host immune response; Innate; Adaptive; COMPLEMENT ACTIVATION; INFECTION;

D O I：

10.1016/j.beha.2022.101401

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The SARS-CoV-2 virus has complex and divergent immune alterations in differing hosts and over disease evolution. Much of the nuanced COVID-19 disease immune dysregulation was originally dominated by innate cytokine changes, which has since been replaced with a more complex picture of innate and adaptive changes characterized by simultaneous hyperinflammatory and immunosuppressive phenomena in effector cells. These intricacies are summarized in this review as well as potential relevance from acute infection to a multisystem inflammatory syndrome commonly seen in children. Additional consideration is made for the influence of variant to variant host cellular changes and the impact of potential vaccination upon these phenotypes. Finally, therapeutic benefit for immune alterations are discussed.

引用

页数：8

共 50 条

[41] T-cell dysregulation in COVID-19
Kalfaoglu, Bahire
Almeida-Santos, Jose
Tye, Chanidapa Adele
Satou, Yorifumi
Ono, Masahiro
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2021, 538 : 204 - 210
[42] Dysregulation of lung myeloid cells in COVID-19
Salomé B.
Magen A.
Nature Reviews Immunology, 2020, 20 (5) : 277 - 277
[43] Dysregulation of Pulmonary Responses in Severe COVID-19
Wu, Dandan
Yang, Xuexian O.
VIRUSES-BASEL, 2021, 13 (06):
[44] Immunometabolic Dysregulation at the Intersection of Obesity and COVID-19
Khwatenge, Collins N.
Pate, Marquette
Miller, Laura C.
Sang, Yongming
FRONTIERS IN IMMUNOLOGY, 2021, 12
[45] Myeloid dysregulation and therapeutic intervention in COVID-19
Gu, Runxia
Mao, Tianyang
Lu, Qiao
Su, Tina Tianjiao
Wang, Jun
SEMINARS IN IMMUNOLOGY, 2021, 55
[46] Re: "Immunothrombotic dysregulation in chagas disease and COVID-19: a comparative study of anticoagulation"
Hasslocher-Moreno, Alejandro Marcel
MOLECULAR AND CELLULAR BIOCHEMISTRY, 2022, 477 (04) : 1093 - 1094
[47] Immune treatment in COVID-19
Menendez, Rosario
Gonzalez, Paula
Latorre, Ana
Mendez, Raul
REVISTA ESPANOLA DE QUIMIOTERAPIA, 2022, 35 : 59 - 63
[48] Atherosclerosis licenses for an exceeding immune response in COVID-19 disease
Leberzammer, J.
Abplanalp, W. T.
Glaser, S. F.
Schumacher, B.
Merten, M.
Katschke, M. T.
John, D.
Vehreschild, M.
Zeiher, A.
Dimmeler, S.
Cremer, S.
EUROPEAN HEART JOURNAL, 2022, 43 : 3082 - 3082
[49] Epigenetic immune monitoring for COVID-19 disease course prognosis
Samans, Bjorn
Chornet, Marta Rossello
Chornet, Araceli Rossello
Jung, Janine
Schildknecht, Konstantin
Lozza, Laura
Zaragoza, Lourdes Alos
Laforet, Javier Hernandez
Babel, Nina
Olek, Sven
FRONTIERS IN IMMUNOLOGY, 2023, 14
[50] SEVERE/REFRACTORY IMMUNE THROMBOCYTOPENIA IN MILD COVID-19 DISEASE
Menon, Trishala
Richard, Irvin
Marks, Edward
Schmitt, Bradley
Machani, Sathyanarayana
CHEST, 2021, 160 (04) : 349A - 349A

← 1 2 3 4 5 →